ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi-Aventis announced that it has embarked on a plan to "develop new growth platforms in light of the important challenges of patent expirations and declining R&D productivity facing the pharmaceutical industry." The French drugmaker is simplifying its organizational structure and updating its research approach to emphasize external collaborations. The company says it is looking to complement recent acquisitions in consumer products and generic drugs. And it has named Elias A. Zerhouni, former NIH director, as scientific adviser to both its CEO and head of research.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X